APA aipamena

Egerer, G., Eisenlohr, K., Gronkowski, M., Burhenne, J., Riedel, K., & Mikus, G. (2010). The NK(1) receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Blackwell Science Inc.

Chicago Style aipamena

Egerer, Gerlinde, Kathrin Eisenlohr, Martina Gronkowski, Juergen Burhenne, Klaus-Dieter Riedel, and Gerd Mikus. The NK(1) Receptor Antagonist Aprepitant Does Not Alter the Pharmacokinetics of High-dose Melphalan Chemotherapy in Patients With Multiple Myeloma. Blackwell Science Inc, 2010.

MLA aipamena

Egerer, Gerlinde, et al. The NK(1) Receptor Antagonist Aprepitant Does Not Alter the Pharmacokinetics of High-dose Melphalan Chemotherapy in Patients With Multiple Myeloma. Blackwell Science Inc, 2010.